2021
Applicability of Transcatheter Aortic Valve Replacement Trials to Real-World Clinical Practice Findings From EXTEND-CoreValve
Butala NM, Secemsky E, Kazi DS, Song Y, Strom JB, Faridi KF, Brennan JM, Elmariah S, Shen C, Yeh RW. Applicability of Transcatheter Aortic Valve Replacement Trials to Real-World Clinical Practice Findings From EXTEND-CoreValve. JACC Cardiovascular Interventions 2021, 14: 2112-2123. PMID: 34620389, PMCID: PMC8855223, DOI: 10.1016/j.jcin.2021.08.006.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacement (TAVR) trialsReal-world patientsReal-world populationTrial patientsPivotal trialsClinical practiceTreatment effectsReplacement trialsAbsolute reductionClinical practice findingsU.S. clinical practiceCharacteristics of patientsCongestive heart failureTrial treatment effectPatient characteristicsTrial cohortHeart failureMedicare cohortAbsolute benefitConventional therapyClinical trialsInverse probability weightingMedicare patientsTAVRMedicare beneficiaries
2020
Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment–Elevation Myocardial Infarction in the United States
Faridi KF, Garratt KN, Kennedy KF, Maddox TM, Secemsky EA, Butala NM, Yeh RW. Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment–Elevation Myocardial Infarction in the United States. Circulation Cardiovascular Quality And Outcomes 2020, 13: e006275. PMID: 32156164, DOI: 10.1161/circoutcomes.119.006275.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiologistsCardiology Service, HospitalClopidogrelDrug UtilizationFemaleHemorrhageHumansMaleMiddle AgedPatient DischargePercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPractice Patterns, Physicians'Prasugrel HydrochloridePurinergic P2Y Receptor AntagonistsReceptors, Purinergic P2Y12RegistriesRetrospective StudiesRisk AssessmentRisk FactorsST Elevation Myocardial InfarctionTicagrelorTime FactorsTreatment OutcomeUnited StatesConceptsST-segment elevation myocardial infarctionP2Y12 inhibitor usePotent P2Y12 inhibitorsP2Y12 inhibitorsSTEMI patientsMyocardial infarctionInhibitor useClopidogrel usePrior percutaneous coronary interventionNew P2Y12 inhibitorsSubstantial hospital variationUse of ticagrelorElevation myocardial infarctionPercutaneous coronary interventionRisk of deathStrongest clinical predictorsNational utilization ratesBackground TicagrelorHospital quartilesCoronary interventionPatient characteristicsClinical predictorsTicagrelor useHospital variationRetrospective study